Pfizer (NYSE:PFE) Stock Gets Price Target Bump from Freedom Broker

Pfizer (NYSE:PFE) had its target price lifted by analysts at Freedom Broker from $33.00 to $34.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Freedom Broker‘s price target points to a potential upside of 15.72% from the stock’s previous close.

A number of other research analysts also recently issued reports on PFE. Guggenheim boosted their price objective on Pfizer from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday. Argus set a $40.00 price target on shares of Pfizer in a report on Wednesday. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. FBN Securities set a $34.00 price objective on shares of Pfizer in a research note on Friday. Finally, Bank of America reduced their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Six research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $30.39.

Pfizer Stock Performance

Shares of PFE traded down $0.50 on Friday, reaching $29.38. The company’s stock had a trading volume of 48,291,518 shares, compared to its average volume of 39,936,480. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.42 and a quick ratio of 0.96. The stock has a market capitalization of $167.46 billion, a P/E ratio of 41.97, a PEG ratio of 2.04 and a beta of 0.31. The stock’s 50 day simple moving average is $28.74 and its two-hundred day simple moving average is $26.90. Pfizer has a 12-month low of $23.62 and a 12-month high of $31.44.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.13. Pfizer had a net margin of 6.34% and a return on equity of 19.88%. The business had revenue of $16.58 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same period in the prior year, the company earned $0.87 earnings per share. The firm’s revenue was down .4% on a year-over-year basis. Research analysts forecast that Pfizer will post 3.02 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pfizer

Institutional investors and hedge funds have recently modified their holdings of the stock. TOWER TRUST & INVESTMENT Co boosted its holdings in Pfizer by 1.9% during the 3rd quarter. TOWER TRUST & INVESTMENT Co now owns 19,322 shares of the biopharmaceutical company’s stock valued at $551,000 after acquiring an additional 357 shares during the period. Angeles Wealth Management LLC increased its stake in Pfizer by 2.2% during the second quarter. Angeles Wealth Management LLC now owns 17,009 shares of the biopharmaceutical company’s stock worth $410,000 after purchasing an additional 358 shares during the period. Manchester Financial Inc. lifted its position in shares of Pfizer by 2.9% during the second quarter. Manchester Financial Inc. now owns 13,168 shares of the biopharmaceutical company’s stock worth $317,000 after purchasing an additional 365 shares in the last quarter. Signature Equity Partners LLC lifted its position in shares of Pfizer by 22.9% during the third quarter. Signature Equity Partners LLC now owns 2,067 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 385 shares in the last quarter. Finally, Delta Financial Advisors LLC boosted its stake in shares of Pfizer by 1.6% in the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after purchasing an additional 398 shares during the period. Institutional investors own 68.36% of the company’s stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s third-quarter results beat analyst expectations, and the company raised its 2026 earnings outlook. Reports also highlighted momentum from newer products, although margin pressure remains a concern. Pfizer Q3 Earnings Rebuild Confidence As New Drugs Gain Ground
• Positive Sentiment: Guggenheim reiterated a Buy view and raised its price target to $33 from $31, signaling potential upside in the analyst’s view. Pfizer Receives a Buy from Guggenheim
• Neutral Sentiment: Pfizer updated an ulcerative-colitis treatment-pattern study and advanced a Phase 3 RSV-vaccine study in high-risk children. The announcements describe ongoing research; no efficacy or safety results were provided in the summaries. Pfizer Advances Phase 3 RSV Vaccine Study
• Negative Sentiment: DZ Bank cut its rating on Pfizer from Buy to Hold, a less favorable view that may temper optimism from other analysts. Pfizer also lagged in a news report focused on Moderna’s earnings-driven gain, though that comparison is not a change in Pfizer’s fundamentals. DZ Bank recommendations Moderna Climbs as Pfizer Dips

Pfizer Company Profile